Published in J Neurooncol on February 01, 1993
Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol (1990) 18.71
Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst (1999) 6.51
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst (1998) 5.30
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol (2004) 4.46
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2000) 2.32
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res (2001) 2.28
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol (2011) 2.13
Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg (2000) 1.82
Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol (2001) 1.77
Radiation therapy for brain metastases. Ann Neurol (1980) 1.68
Glioma classification: a molecular reappraisal. Am J Pathol (2001) 1.65
Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol (1988) 1.64
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci U S A (1982) 1.59
Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol (1998) 1.56
Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys (1992) 1.54
Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol (1999) 1.52
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology (2011) 1.48
PCV for oligodendroglial tumors: in search of prognostic factors for response and survival. Can J Neurol Sci (2001) 1.47
DNA methyltransferase inhibitors-state of the art. Ann Oncol (2002) 1.43
Measuring bias in uncontrolled brain tumor trials--to randomize or not to randomize? Can J Neurol Sci (1997) 1.43
Oligodendroglioma. Cancer Invest (1996) 1.39
Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res (2001) 1.38
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol (1990) 1.35
Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys (2000) 1.32
Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol (1996) 1.31
Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol (2000) 1.30
Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg (1989) 1.27
Pulmonary blastoma: case report of a patient with a 7-year remission and review of chemotherapy experience in the world literature. Cancer (1998) 1.25
Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys (1999) 1.18
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol (2006) 1.17
Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun (1985) 1.16
Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci (1998) 1.15
Identification of glial filament protein and vimentin in the same intermediate filament system in human glioma cells. Proc Natl Acad Sci U S A (1984) 1.14
Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. J Clin Oncol (1994) 1.14
Monoclonal antibodies to three widely distributed human cell surface antigens. Hybridoma (1983) 1.14
p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J Natl Cancer Inst (1994) 1.13
Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol (1994) 1.13
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology (1991) 1.13
Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stat (1999) 1.12
An intermediate filament-associated protein, p50, recognized by monoclonal antibodies. J Cell Biol (1983) 1.11
Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer (2005) 1.09
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood (2000) 1.07
Primary cerebral fibrosarcomas. Clinicopathologic study and review of the literature. Cancer (1993) 1.06
The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer (2004) 1.06
Postoperative contrast enhancement in patients with brain tumor. Ann Neurol (1985) 1.05
Syncope from head and neck cancer. J Neurooncol (1983) 1.05
Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys (2001) 1.04
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol (2001) 1.04
Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol (1995) 1.04
Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg (1994) 1.03
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs (2006) 1.03
Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology (1991) 1.03
Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol (1999) 1.02
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Int J Gynecol Cancer (2003) 1.02
Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1999) 1.01
Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial. Ann Oncol (2012) 1.01
Steroid-induced CT changes in patients with recurrent malignant glioma. Neurology (1988) 0.99
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol (1998) 0.98
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology (1999) 0.95
Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol (2009) 0.94
Chemotherapy for malignant gliomas. Baillieres Clin Neurol (1996) 0.94
Primary diffuse leptomeningeal oligodendroglioma. Case report. J Neurosurg (1995) 0.94
Selection bias in clinical trials of anaplastic glioma. Ann Neurol (1989) 0.94
Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol (1996) 0.93
Chemotherapy for brain tumors. Oncology (Williston Park) (1998) 0.93
Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy. Cancer Res (2000) 0.93
Selection bias, survival, and brachytherapy for glioma. J Neurosurg (1992) 0.93
Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res (2001) 0.91
Docetaxel: current status and future prospects. J Clin Oncol (1995) 0.91
Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas. Brain Pathol (1999) 0.90
Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery (1992) 0.90
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol (2007) 0.90
Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol (1999) 0.89
Comparison of metastatic properties of a variety of mouse, rat, and human cells in assays in nude mice and chick embryos. In Vivo (1991) 0.89
Post-surgical contrast enhancement mimicking residual brain tumour. Can J Neurol Sci (1985) 0.89
Expression of common acute lymphoblastic leukemia-associated antigen on germ cell tumor. Am J Med (1986) 0.88
A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity. Cancer Chemother Pharmacol (2001) 0.88
Treatment of oligodendroglioma: an update. Neuro Oncol (1999) 0.88
Efficacy of 2'-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst (1988) 0.88